$SAVA – Cassava Sciences: A Timeline

For those of you who are unaware of Cassava Sciences and what they do, they are a clinical stage Biotech company based out of Austin, TX that is in the process of developing their drug Simufilam. This is their solution to early stages of Alzheimer’s. This drug is currently in the early stages of Phase 3 of the FDA approval process. If approved, this drug will be ground breaking for several reasons:

1) It is a pill, thus non invasive.
2) It is not based on the conventional amyloid hypothesis.
3) Would be a cheap alternative to other potential prospects attempting to tackle the problem.
4) Has not shown any negative side effects during the current trials.

The current problem though, which those of you who are familiar with $SAVA is the amount of FUD that has been created as a result from bad acting short sellers looking to profit from blatant misinformation.

Let’s look at a timeline.

• 2nd Quarter of 2021 $SAVA started to gain traction as promising results started to come through it’s phase 2 trials.
• $SAVA hit an ATH of $123.38 in July of 2021.
• Since then, it has been a victim of scrutiny and multiple short and distort campaigns involving news outlets and individuals on social media.
• These bad actors (self admitted short sellers) filed a citizen’s petition to half phase 2 trials for Simufilam to the FDA.
• In December of 2021, a scientific journal found no evidence of supposed “data manipulation” that had been alleged.
• In February of this year, that request was denied.
• In August of this year, another publication cleared $SAVA of supposed “data manipulation”.

• In November, $SAVA files a lawsuit against the “short and distort” short sellers who have bombarded this company a series of allegations that are not based in science and only based on financial gain.

• No insiders have sold any of their positions in this company. In fact, there have been several insider buys this year. Most notable Sanford Robertson buying 100,000 shares of common stock back in August.

• The company has issued 50 million dollars in direct offering of common stock.

• $SAVA has completed its open label study with results coming in the coming days/weeks.

Since the day of the announced common stock purchase (11/22) the stock has risen over 20%. Exciting times ahead.

This is not financial advice